Their mechanism of action prevents the inactivation of cytotoxic T-cells, allowing for its cytotoxic response. However, the upregulation of the immune system by ICI also leads to many undesired adverse events known as immune-related adverse events (irAEs), ranging from dermatologic manifestations, ...
Based on its mechanism of action and data from animal studies, IMFINZI can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. In females of reproductive potential, verify pregnancy status prior to initiating IMFINZI and advise them...
Because of the potential interference with the pharmacodynamic activity and efficacy of durvalumab, the use of systemic corticosteroids or immunesuppressants [with the exception of physiological doses of systemic corticosteroids (i.e. ≤ 10 mg/day prednisone or equivalent)] before starting durvalumab is...
Based on its mechanism of action and data from animal studies, IMFINZI can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of durvalumab to cynomolgus monkeys from the onset of organogenesis through delivery resulted in increased premature delivery,...
Durvalumab did not appear to antagonize the gefitinib’s mechanism of action [epidermal growth factor receptor (EGFR) inhibition] in patients with NSCLC in a phase I study [19]. 2.2 Pharmacokinetics Exposure to durvalumab increased dose-proportionally at ≥3 mg/kg in cancer patients, with steady...
Interrupt or slow the rate of infusion for Grade 1–2 infusion-related reactions and permanently discontinue for Grade 3–4 infusion-related reactions.Embryo-Fetal ToxicityBased on its mechanism of action and data from animal studies, IMFINZI can cause fetal harm when administered to a pregnant ...
Based on their mechanism of action and data from animal studies, IMFINZI and IMJUDO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. In females of reproductive potential, verify pregnancy status prior to initiating IMFINZI and ...
Based on its mechanism of action and data from animal studies, IMFINZI can cause fetal harm when administered to a pregnant woman. There are no data on the use of IMFINZI in pregnant women. Advise pregnant women of the potential risk ...
Based on their mechanism of action and data from animal studies, IMFINZI and IMJUDO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. In females of reproductive potential, verify pregnancy status prior to initiating IMFINZI and IM...
Therapeutic importance, general and endocrine adverse effects of immune checkpoint inhibitors I: mechanism of action and therapeutic use The tumor microenvironment has a fundamental role in the escape phenomenon of cancerous cells from the immune surveillance, the immunological protective me... IZ Kun,...